Pfizer acquisition of Therachon : US pharma giant Pfizer has completed its previously announced acquisition of Swiss biotech company Therachon, which is focused on rare diseases, in a deal worth up to $810 million, as per the latest pharma acquisition news. The clinical-stage Therachon is currently engaged in developing treatment of achondroplasia and short bowel […]
US pharma giant Pfizer has opened Andover Clinical Manufacturing Facility (ACMF), a new 175,000sft biologics clinical manufacturing facility built with an investment of over $200 million in Andover, Massachusetts. The biologics clinical manufacturing facility will be used for the development and production of complex biologics and vaccines and is expected to expand Pfizer’s BioTherapeutics Pharmaceutical […]
New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover the treatment of hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. Latest Ibrance FDA approval Under the new indication approved […]
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a significant boost to Pfizer’s lung cancer drug, Vizimpro (dacomitinib), recommending its approval as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). This recommendation specifically targets patients with epidermal growth factor receptor […]
In a significant step towards expanding biosimilar access, Pfizer and AbbVie have resolved all global intellectual property disputes concerning Pfizer’s proposed biosimilar to AbbVie’s blockbuster rheumatoid arthritis drug, Humira (adalimumab). This agreement marks a major milestone in Pfizer’s mission to broaden its portfolio of biosimilar medications, as it acquires a non-exclusive patent license to market […]
Pfizer Inc., a leading US pharmaceutical company, has secured approval from the US Food and Drug Administration (FDA) for Lorbrena (lorlatinib), a groundbreaking treatment for anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC). This approval marks a significant milestone in the fight against a challenging form of cancer, particularly for patients whose […]
Pfizer, the US pharmaceutical giant, has announced the discontinuation of two ongoing clinical trials for its drug domagrozumab (PF-06252616), intended to treat Duchenne muscular dystrophy (DMD). This decision comes after the trials failed to meet primary efficacy endpoints. The trials, identified as B5161002 and B5161004, were designed to evaluate the safety and efficacy of domagrozumab, […]
In a significant advancement in vaccine research, German biotech firm BioNTech has partnered with American pharmaceutical giant Pfizer in a multi-year research and development collaboration valued at $425 million. This strategic alliance is set to revolutionize influenza (flu) prevention with the development of mRNA-based flu vaccines. Under the collaboration, BioNTech and Pfizer will jointly conduct […]
Pfizer Inc. has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for Nivestym (filgrastim-aafi), a biosimilar to Amgen’s Neupogen (filgrastim), for treating neutropenia. This approval is a crucial step in making effective treatments more accessible and affordable for patients suffering from this condition. Neutropenia, characterized by an unusually low […]
In a significant development, Astellas Pharma and Pfizer have announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of their cancer drug Xtandi (enzalutamide) for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC). This marks an important step forward in the treatment options available to patients suffering from this […]